<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK121284" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK121284/" /><meta name="ncbi_pagename" content="X-Linked Protoporphyria - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>X-Linked Protoporphyria - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="X-Linked Protoporphyria" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2019/11/27" /><meta name="citation_author" content="Manisha Balwani" /><meta name="citation_author" content="Robert Desnick" /><meta name="citation_author" content="Porphyrias Consortium of the NIH-Sponsored Rare Diseases Clinical Research Network" /><meta name="citation_pmid" content="23409301" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK121284/" /><meta name="citation_keywords" content="5-aminolevulinate synthase, erythroid-specific, mitochondrial" /><meta name="citation_keywords" content="ALAS2" /><meta name="citation_keywords" content="X-Linked Protoporphyria" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="X-Linked Protoporphyria" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Manisha Balwani" /><meta name="DC.Contributor" content="Robert Desnick" /><meta name="DC.Contributor" content="Porphyrias Consortium of the NIH-Sponsored Rare Diseases Clinical Research Network" /><meta name="DC.Date" content="2019/11/27" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK121284/" /><meta name="description" content="X-linked protoporphyria (XLP) is characterized in affected males by cutaneous photosensitivity (usually beginning in infancy or childhood) that results in tingling, burning, pain, and itching within minutes of sun/light exposure and may be accompanied by swelling and redness. Blistering lesions are uncommon. Pain, which may seem out of proportion to the visible skin lesions, may persist for hours or days after the initial phototoxic reaction. Photosensitivity is lifelong. Multiple episodes of acute photosensitivity may lead to chronic changes of sun-exposed skin (lichenification, leathery pseudovesicles, grooving around the lips) and loss of lunulae of the nails. An unknown proportion of individuals with XLP develop liver disease. Except for those with advanced liver disease, life expectancy is not reduced. The phenotype in heterozygous females ranges from asymptomatic to as severe as in affected males." /><meta name="og:title" content="X-Linked Protoporphyria" /><meta name="og:type" content="book" /><meta name="og:description" content="X-linked protoporphyria (XLP) is characterized in affected males by cutaneous photosensitivity (usually beginning in infancy or childhood) that results in tingling, burning, pain, and itching within minutes of sun/light exposure and may be accompanied by swelling and redness. Blistering lesions are uncommon. Pain, which may seem out of proportion to the visible skin lesions, may persist for hours or days after the initial phototoxic reaction. Photosensitivity is lifelong. Multiple episodes of acute photosensitivity may lead to chronic changes of sun-exposed skin (lichenification, leathery pseudovesicles, grooving around the lips) and loss of lunulae of the nails. An unknown proportion of individuals with XLP develop liver disease. Except for those with advanced liver disease, life expectancy is not reduced. The phenotype in heterozygous females ranges from asymptomatic to as severe as in affected males." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK121284/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/epp-xl/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK121284/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE881C1BE04170D100000000085402F6.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK121284_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK121284_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/opd/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/x-scid/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK121284_"><span class="title" itemprop="name">X-Linked Protoporphyria</span></h1><p class="contrib-group"><span itemprop="author">Manisha Balwani</span>, MD, MS, FACMG, <span itemprop="author">Robert Desnick</span>, MD, PhD, FACMG; <span itemprop="author">Porphyrias Consortium of the NIH-Sponsored Rare Diseases Clinical Research Network</span>.</p><a data-jig="ncbitoggler" href="#__NBK121284_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK121284_ai__"><div class="contrib half_rhythm"><span itemprop="author">Manisha Balwani</span>, MD, MS, FACMG<div class="affiliation small">Icahn School of Medicine at Mount Sinai<br />New York, New York<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.mssm@inawlab.ahsinam" class="oemail">ude.mssm@inawlab.ahsinam</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Robert Desnick</span>, MD, PhD, FACMG<div class="affiliation small">Icahn School of Medicine at Mount Sinai<br />New York, New York<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.mssm@kcinsed.trebor" class="oemail">ude.mssm@kcinsed.trebor</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Porphyrias Consortium of the NIH-Sponsored Rare Diseases Clinical Research Network</span><sup><a href="#epp-xl.Tb.an3" class="bk_pop">*</a></sup></div></div><p class="small">Initial Posting: <span itemprop="datePublished">February 14, 2013</span>; Last Update: <span itemprop="dateModified">November 27, 2019</span>.</p><p><em>Estimated reading time: 21 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="epp-xl.Summary" itemprop="description"><h2 id="_epp-xl_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p><a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> protoporphyria (XLP) is characterized in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males by cutaneous photosensitivity (usually beginning in infancy or childhood) that results in tingling, burning, pain, and itching within minutes of sun/light exposure and may be accompanied by swelling and redness. Blistering lesions are uncommon. Pain, which may seem out of proportion to the visible skin lesions, may persist for hours or days after the initial phototoxic reaction. Photosensitivity is lifelong. Multiple episodes of acute photosensitivity may lead to chronic changes of sun-exposed skin (lichenification, leathery pseudovesicles, grooving around the lips) and loss of lunulae of the nails. An unknown proportion of individuals with XLP develop liver disease. Except for those with advanced liver disease, life expectancy is not reduced. The <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> females ranges from asymptomatic to as severe as in affected males.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of XLP is established in a male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with markedly increased free erythrocyte protoporphyrin and zinc-chelated erythrocyte protoporphyrin by identification of a <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> pathogenic <a class="def" href="/books/n/gene/glossary/def-item/gain-of-function/">gain-of-function</a> variant in <i>ALAS2</i> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p><p>The diagnosis of XLP is established in a female <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with increased free erythrocyte protoporphyrin and zinc-chelated erythrocyte protoporphyrin by identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> pathogenic <a class="def" href="/books/n/gene/glossary/def-item/gain-of-function/">gain-of-function</a> variant in <i>ALAS2</i> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> The phototoxicity and subsequent pain can be reduced by the administration of afamelanotide, an &#x003b1;-melanocyte-stimulating hormone analog. Otherwise, the only effective treatment is prevention of the painful attacks by avoidance of sun/light (including the long-wave ultraviolet light that passes through window glass) through use of protective clothing (e.g., long sleeves, gloves, wide-brimmed hats, protective tinted glass for cars and windows). Although topical sunscreens are typically not useful, some tanning products containing creams that cause increased pigmentation may be helpful. Oral Lumitene&#x02122; (&#x003b2;-carotene) has been used to improve tolerance to sunlight by causing mild skin discoloration due to carotenemia; however, a systematic review of treatment options showed no evidence of efficacy. Vitamin D supplementation is recommended to prevent vitamin D insufficiency due to sun avoidance.</p><p>Severe liver complications are difficult to treat: cholestyramine and other porphyrin absorbents (to interrupt the enterohepatic circulation of protoporphyrin and promote its fecal excretion) and plasmapheresis and intravenous hemin are sometimes beneficial. Liver transplantation can be a lifesaving measure in individuals with severe protoporphyric liver disease; combined bone marrow and liver transplantation is indicated in those with liver failure to prevent future damage to the allografts.</p><p><i>Surveillance:</i> Monitoring of: hepatic function every 6-12 months and hepatic imaging if cholelithiasis is suspected; erythrocyte protoporphyrin levels (free and zinc-chelated), hematologic indices, and iron profile annually; vitamin D 25-OH levels.</p><p><i>Agents/circumstances to avoid:</i> Sunlight and UV light; for those with hepatic dysfunction, drugs that may induce cholestasis (e.g., estrogens). For those with cholestatic liver failure, protective filters should be used for the operating room lights for liver transplant surgery to avoid phototoxic damage.</p><p><i>Evaluation of relatives at risk:</i> If the <i>ALAS2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, at-risk relatives can be tested as newborns or infants so that those with the pathogenic variant can benefit from early intervention (sun protection) and future monitoring for signs of liver dysfunction.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>By definition, XLP is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> manner. Affected males transmit the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> to all of their daughters and none of their sons. Women with an <i>ALAS2</i> pathogenic variant have a 50% chance of transmitting the variant to each child. Once the <i>ALAS2</i> pathogenic variant has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, <a class="def" href="/books/n/gene/glossary/def-item/heterozygote/">heterozygote</a> testing for at-risk female relatives, prenatal testing for pregnancies at increased risk, and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-testing/">preimplantation genetic testing</a> are possible.</p></div></div><div id="epp-xl.Diagnosis"><h2 id="_epp-xl_Diagnosis_">Diagnosis</h2><p>There are no established guidelines or diagnostic algorithms.</p><div id="epp-xl.Suggestive_Findings"><h3>Suggestive Findings</h3><p><a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> protoporphyria (XLP) should be suspected in individuals with the following clinical findings and initial laboratory findings.</p><p><b>Clinical findings</b></p><ul><li class="half_rhythm"><div class="half_rhythm">Cutaneous photosensitivity, usually beginning in childhood</div></li><li class="half_rhythm"><div class="half_rhythm">Burning, tingling, pain, and itching of the skin (the most common findings); may occur within minutes of sun/light exposure, followed later by erythema and swelling</div></li><li class="half_rhythm"><div class="half_rhythm">Painful symptoms; may occur without obvious skin damage</div></li><li class="half_rhythm"><div class="half_rhythm">Absent or sparse blisters and bullae</div><div class="half_rhythm">Note: The absence of skin damage (e.g., scarring), vesicles, and bullae often make it difficult to suspect the diagnosis.</div></li><li class="half_rhythm"><div class="half_rhythm">Hepatic complications, particularly cholestatic liver disease, may develop in fewer than 5% of patients.</div></li></ul><p><b>Initial laboratory findings.</b> Detection of markedly increased free erythrocyte protoporphyrin and zinc-chelated erythrocyte protoporphyrin is the most sensitive biochemical diagnostic test for XLP (<a class="figpopup" href="/books/NBK121284/table/epp-xl.T.biochemical_characteristics_of/?report=objectonly" target="object" rid-figpopup="figeppxlTbiochemicalcharacteristicsof" rid-ob="figobeppxlTbiochemicalcharacteristicsof">Table 1</a>).</p><p>Note: It is essential to use an assay for erythrocyte protoporphyrin that distinguishes between free protoporphyrin and zinc-chelated protoporphyrin to differentiate XLP from erythropoietic protoporphyria (EPP-AR) and several other conditions that may lead to elevation of erythrocyte protoporphyrins (see <a class="figpopup" href="/books/NBK121284/table/epp-xl.T.biochemical_characteristics_of/?report=objectonly" target="object" rid-figpopup="figeppxlTbiochemicalcharacteristicsof" rid-ob="figobeppxlTbiochemicalcharacteristicsof">Table 1</a>, footnotes 3 and 4).</p><div id="epp-xl.T.biochemical_characteristics_of" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Biochemical Characteristics of X-Linked Protoporphyria (XLP)</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK121284/table/epp-xl.T.biochemical_characteristics_of/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__epp-xl.T.biochemical_characteristics_of_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_epp-xl.T.biochemical_characteristics_of_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Enzyme Defect</th><th id="hd_h_epp-xl.T.biochemical_characteristics_of_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Enzyme Activity</th><th id="hd_h_epp-xl.T.biochemical_characteristics_of_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Erythrocytes</th><th id="hd_h_epp-xl.T.biochemical_characteristics_of_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Urine</th><th id="hd_h_epp-xl.T.biochemical_characteristics_of_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Stool</th><th id="hd_h_epp-xl.T.biochemical_characteristics_of_1_1_1_6" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Other</th></tr></thead><tbody><tr><td headers="hd_h_epp-xl.T.biochemical_characteristics_of_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Erythroid-specific 5-aminolevulinate synthase 2 (ALAS2)</td><td headers="hd_h_epp-xl.T.biochemical_characteristics_of_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;100% of normal&#x000a0;<sup>1</sup></td><td headers="hd_h_epp-xl.T.biochemical_characteristics_of_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Free protoporphyrin/<br />zinc-chelated protoporphyrin ratio 90:10 to 50:50&#x000a0;<sup>2,&#x000a0;3,&#x000a0;4</sup></td><td headers="hd_h_epp-xl.T.biochemical_characteristics_of_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Protoporphyrins not detectable</td><td headers="hd_h_epp-xl.T.biochemical_characteristics_of_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Protoporphyrin normal or increased</td><td headers="hd_h_epp-xl.T.biochemical_characteristics_of_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Plasma porphyrins increased&#x000a0;<sup>5</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="epp-xl.TF.1.1"><p class="no_margin">Increased enzyme activity is due to <i>ALAS2</i> pathogenic <a class="def" href="/books/n/gene/glossary/def-item/gain-of-function/">gain-of-function</a> variants in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 11. Note: Lymphocyte ferrochelatase activity is normal.</p></div></dd><dt>2. </dt><dd><div id="epp-xl.TF.1.2"><p class="no_margin">Many assays for erythrocyte protoporphyrin or "free erythrocyte protoporphyrin" measure both zinc-chelated protoporphyrin and free protoporphyrin. Free protoporphyrin is distinguished from zinc-chelated protoporphyrin by ethanol extraction or HPLC.</p></div></dd><dt>3. </dt><dd><div id="epp-xl.TF.1.3"><p class="no_margin">Protoporphyrins (usually zinc-chelated protoporphyrin) are also increased in lead poisoning, iron deficiency, anemia of chronic disease, and various hemolytic disorders, as well as in those porphyrias caused by <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants (e.g., harderoporphyria).</p></div></dd><dt>4. </dt><dd><div id="epp-xl.TF.1.4"><p class="no_margin">In erythropoietic protoporphyria, free protoporphyrin levels are elevated significantly as compared to zinc-chelated protoporphyrin (see <a href="#epp-xl.Differential_Diagnosis">Differential Diagnosis</a>).</p></div></dd><dt>5. </dt><dd><div id="epp-xl.TF.1.5"><p class="no_margin">Plasma total porphyrins are increased in porphyrias with cutaneous manifestations including XLP. If plasma porphyrins are increased, the fluorescence emission spectrum of plasma porphyrins at neutral pH can be characteristic and can distinguish XLP and EPP-AR from other porphyrias. The emission maximum in XLP and EPP-AR occurs at 634 nm.</p></div></dd></dl></div></div></div></div><div id="epp-xl.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p><b>Male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The diagnosis of <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> protoporphyria (XLP) <b>is established</b> in a male proband with markedly increased free erythrocyte protoporphyrin and zinc-chelated erythrocyte protoporphyrin by identification of a <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> pathogenic <a class="def" href="/books/n/gene/glossary/def-item/gain-of-function/">gain-of-function</a> variant in <i>ALAS2</i> (encoding erythroid specific 5-aminolevulinate synthase 2) on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK121284/table/epp-xl.T.molecular_genetic_testing_used/?report=objectonly" target="object" rid-figpopup="figeppxlTmoleculargenetictestingused" rid-ob="figobeppxlTmoleculargenetictestingused">Table 2</a>).</p><p><b>Female <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The diagnosis of <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> protoporphyria (XLP) <b>is established</b> in a female proband with increased free erythrocyte protoporphyrin and zinc-chelated erythrocyte protoporphyrin by identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> pathogenic <a class="def" href="/books/n/gene/glossary/def-item/gain-of-function/">gain-of-function</a> variant in <i>ALAS2</i> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK121284/table/epp-xl.T.molecular_genetic_testing_used/?report=objectonly" target="object" rid-figpopup="figeppxlTmoleculargenetictestingused" rid-ob="figobeppxlTmoleculargenetictestingused">Table 2</a>).</p><div id="epp-xl.Molecular_Genetic_Testing"><h4>Molecular Genetic Testing</h4><p>Molecular genetic testing approaches can include a combination of <b><a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted testing</b> (single-gene testing, <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a>).</p><p><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of <i>ALAS2</i> detects small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants.</p><p>Note: All <i>ALAS2</i> pathogenic variants associated with XLP reported to date are <a class="def" href="/books/n/gene/glossary/def-item/gain-of-function/">gain-of-function</a> <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, or <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> variants in the last <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> (exon 11; see <a href="#epp-xl.Molecular_Genetics">Molecular Genetics</a>). Therefore, <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of all other exons, as well as testing for <a class="def" href="/books/n/gene/glossary/def-item/haploinsufficiency/">haploinsufficiency</a> or <a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> (overexpression) is not indicated based on current knowledge.</p><div id="epp-xl.T.molecular_genetic_testing_used" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in X-Linked Protoporphyria</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK121284/table/epp-xl.T.molecular_genetic_testing_used/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__epp-xl.T.molecular_genetic_testing_used_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_epp-xl.T.molecular_genetic_testing_used_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_epp-xl.T.molecular_genetic_testing_used_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_epp-xl.T.molecular_genetic_testing_used_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by Method</th></tr></thead><tbody><tr><td headers="hd_h_epp-xl.T.molecular_genetic_testing_used_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>ALAS2</i></td><td headers="hd_h_epp-xl.T.molecular_genetic_testing_used_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_epp-xl.T.molecular_genetic_testing_used_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">All variants reported to date&#x000a0;<sup>4</sup></td></tr><tr><td headers="hd_h_epp-xl.T.molecular_genetic_testing_used_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>5</sup></td><td headers="hd_h_epp-xl.T.molecular_genetic_testing_used_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 6</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="epp-xl.TF.2.1"><p class="no_margin">See <a href="/books/NBK121284/#epp-xl.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="epp-xl.TF.2.2"><p class="no_margin">See <a href="#epp-xl.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="epp-xl.TF.2.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="epp-xl.TF.2.4"><p class="no_margin"><a class="bk_pop" href="#epp-xl.REF.balwani.2019">Balwani [2019]</a></p></div></dd><dt>5. </dt><dd><div id="epp-xl.TF.2.5"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd></dl></div></div></div><p>6. All <i>ALAS2</i> pathogenic variants reported to date are <a class="def" href="/books/n/gene/glossary/def-item/gain-of-function/">gain-of-function</a> <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants; thus, testing for <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> (<a class="def" href="/books/n/gene/glossary/def-item/haploinsufficiency/">haploinsufficiency</a>) or <a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> (overexpression) is not indicated.</p></div></div></div><div id="epp-xl.Clinical_Characteristics"><h2 id="_epp-xl_Clinical_Characteristics_">Clinical Characteristics</h2><div id="epp-xl.Clinical_Description"><h3>Clinical Description</h3><p>The natural history of <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> protoporphyria (XLP) is not as well characterized as that of the <a href="/books/n/gene/epp-ar/">autosomal recessive type of erythropoietic protoporphyria</a> (EPP-AR) (see <a href="#epp-xl.Differential_Diagnosis">Differential Diagnosis</a>). A natural history study from the US described 22 individuals with XLP from seven unrelated families [<a class="bk_pop" href="#epp-xl.REF.balwani.2017.789">Balwani et al 2017</a>].</p><div id="epp-xl.XLP_in_Males"><h4>XLP in Males</h4><p>While the cutaneous manifestations in males with XLP are similar to those of EPP, <a class="bk_pop" href="#epp-xl.REF.balwani.2017.789">Balwani et al [2017]</a> suggest that males with XLP have significantly higher protoporphyrin levels and increased risk of liver dysfunction.</p><p><b>Photosensitivity.</b> Onset of photosensitivity is typically in infancy or childhood (with the first exposure to sun); in most individuals with XLP the photosensitivity is lifelong.</p><p>Most males with XLP develop acute cutaneous photosensitivity within five to 30 minutes following exposure to sun or ultraviolet light. Photosensitivity symptoms are provoked mainly by visible blue-violet light in the Soret band, to a lesser degree in the long-wave UV region.</p><p>The initial symptoms reported are tingling, burning, and/or itching that may be accompanied by swelling and redness. Symptoms vary based on the intensity and duration of sun exposure; pain may be severe and refractory to narcotic analgesics, persisting for hours or days after the initial phototoxic reaction. Symptoms may seem out of proportion to the visible skin lesions. Blistering lesions are uncommon.</p><p>Affected males are also sensitive to sunlight that passes through window glass, which does not block long-wave UVA or visible light.</p><p><b>Cutaneous manifestations.</b> Multiple episodes of acute photosensitivity may lead to chronic changes of sun-exposed skin (lichenification, leathery pseudovesicles, grooving around the lips) and loss of lunulae of the nails. The dorsum of the hands is most notably affected.</p><p>Severe scarring is rare, as are hyper- or hypopigmentation, skin friability, and hirsutism.</p><p>Unlike in other cutaneous porphyrias, blistering and scarring rarely occur.</p><p><b>Hepatobiliary manifestations.</b> Protoporphyrin is not excreted in the urine by the kidneys, but is taken up by the liver and excreted in the bile. Accumulated protoporphyrin in the bile can form stones, reduce bile flow, and damage the liver. Protoporphyric liver disease may cause back pain and severe abdominal pain (especially in the right upper quadrant).</p><p>The information on XLP and liver disease is limited. The risk for liver dysfunction in XLP (observed in 5/31 <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals) is higher than the risk in EPP-AR [<a class="bk_pop" href="#epp-xl.REF.whatley.2008.408">Whatley et al 2008</a>]. A natural history study in the US showed that 40% of males with XLP had a history of abnormal liver enzymes compared to 33% of persons with EPP-AR. Gallstones were seen in 40% of males with XLP and 33.3% of females with XLP compared to 22.1% of individuals with EPP-AR.</p><p>Note that the information on liver involvement presented below is based on experience with liver disease in <a href="/books/n/gene/epp-ar/">autosomal recessive EPP</a>. Gallstones composed in part of protoporphyrin may be symptomatic in individuals with XLP and need to be excluded as a cause of biliary obstruction in persons with hepatic decompensation.</p><p>Life-threatening hepatic complications are preceded by increased levels of plasma and erythrocyte protoporphyrins, worsening hepatic function tests, increased photosensitivity, and increased deposition of protoporphyrins in hepatic cells and bile canaliculi. End-stage liver disease may be accompanied by motor neuropathy, similar to that seen in <a href="/books/n/gene/aip/">acute porphyrias</a>. Comorbid conditions, such as viral hepatitis, alcohol abuse, and use of oral contraceptives, which may impair hepatic function or protoporphyrin metabolism, may contribute to hepatic disease in some [<a class="bk_pop" href="#epp-xl.REF.mcguire.2005.1590">McGuire et al 2005</a>].</p><p><b>Hematologic.</b> Anemia and abnormal iron metabolism can occur in XLP. Mild anemia with microcytosis and hypochromia or occasionally reticulocytosis can be seen; however, hemolysis is absent or mild. In a recent series, 30% of males with XLP and 75% of females with XLP were anemic [<a class="bk_pop" href="#epp-xl.REF.balwani.2017.789">Balwani et al 2017</a>]</p><p><b>Vitamin D deficiency.</b> Persons with XLP who avoid sun/light are at risk for vitamin D deficiency [<a class="bk_pop" href="#epp-xl.REF.holme.2008.211">Holme et al 2008</a>, <a class="bk_pop" href="#epp-xl.REF.spelt.2010.s1">Spelt et al 2010</a>, <a class="bk_pop" href="#epp-xl.REF.wahlin.2011a.278">Wahlin et al 2011a</a>].</p><p><b>Precipitating factors.</b> Unlike the precipitating factors for acute hepatic porphyrias, the only known precipitating factor for XLP is sunlight.</p></div><div id="epp-xl.XLP_in_Females"><h4>XLP in Females</h4><p>The <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of XLP in <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> females, the consequence of random <a class="def" href="/books/n/gene/glossary/def-item/x-chromosome-inactivation/">X-chromosome inactivation</a>, ranges from as severe as in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males to asymptomatic. The median age of symptom onset for females with XLP was 11 years. Following sun exposure, symptom onset ranged from within ten minutes to none [<a class="bk_pop" href="#epp-xl.REF.balwani.2017.789">Balwani et al 2017</a>].</p></div></div><div id="epp-xl.Pathophysiology"><h3>Pathophysiology</h3><p>Bone marrow reticulocytes are thought to be the primary source of the accumulated protoporphyrin that is excreted in bile and feces. Most of the excess protoporphyrin in circulating erythrocytes is found in a small percentage of cells, and the rate of protoporphyrin leakage from these cells is proportional to their protoporphyrin content.</p><p>The skin of persons with XLP is maximally sensitive to visible blue-violet light near 400 nm, which corresponds to the so-called "Soret band" (the narrow peak absorption maximum that is characteristic for protoporphyrin and other porphyrins). When porphyrins absorb light they enter an excited energy state. This energy is presumably released as fluorescence and by formation of singlet oxygen and other oxygen radicals that can produce tissue and vessel damage. This may involve lipid peroxidation, oxidation of amino acids, and cross-linking of proteins in cell membranes.</p><p>Photoactivation of the complement system and release of histamine, kinins, and chemotactic factors may mediate skin damage. Histologic changes occur predominantly in the upper dermis and include deposition of amorphous material containing immunoglobulin, complement components, glycoproteins, glycosaminoglycans, and lipids around blood vessels. Damage to capillary endothelial cells in the upper dermis has been demonstrated immediately after light exposure in this disease [<a class="bk_pop" href="#epp-xl.REF.schneideryin.2000.719">Schneider-Yin et al 2000</a>].</p><p>Long-term observations of patients with protoporphyria generally show little change in protoporphyrin levels in erythrocytes, plasma, and feces [<a class="bk_pop" href="#epp-xl.REF.gou.2018.213">Gou et al 2018</a>]. In contrast, severe hepatic complications, when they occur, often follow increasing accumulation of protoporphyrin in erythrocytes, plasma, and liver. Iron deficiency and factors that impair liver function sometimes contribute. Enterohepatic circulation of protoporphyrin may favor its return and retention in the liver, especially when liver function is impaired. Liver damage probably results at least in part from protoporphyrin accumulation itself. As this porphyrin is insoluble, it tends to form crystalline structures in liver cells, can impair mitochondrial functions in liver cells, and can decrease hepatic bile formation and flow [<a class="bk_pop" href="#epp-xl.REF.anderson.2001">Anderson et al 2001</a>].</p></div><div id="epp-xl.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>Because of the limited number of families known to have XLP, no <a class="def" href="/books/n/gene/glossary/def-item/genotype-phenotype-correlations/">genotype-phenotype correlations</a> have been identified.</p></div><div id="epp-xl.Penetrance"><h3>Penetrance</h3><p>XLP appears to be 100% penetrant in males.</p><p>In <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> females, clinical variability is attributed to random <a class="def" href="/books/n/gene/glossary/def-item/x-chromosome-inactivation/">X-chromosome inactivation</a>. Symptomatic females have been reported [<a class="bk_pop" href="#epp-xl.REF.whatley.2008.408">Whatley et al 2008</a>, <a class="bk_pop" href="#epp-xl.REF.di_pierro.2009.315">Di Pierro et al 2009</a>].</p></div><div id="epp-xl.Nomenclature"><h3>Nomenclature</h3><p>Although sometimes considered a synonym for XLP, the term "erythropoietic protoporphyria, <a class="def" href="/books/n/gene/glossary/def-item/x-linked-dominant/">X-linked dominant</a>" is incorrect and should not be used: in all X-linked metabolic disorders the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> females can range from asymptomatic to as severe as that seen in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male relatives.</p></div><div id="epp-xl.Prevalence"><h3>Prevalence</h3><p>The prevalence of XLP is unknown.</p><ul><li class="half_rhythm"><div>Based on studies from the UK, XLP appears to account for about 2% of individuals with the erythropoietic protoporphyria <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> [<a class="bk_pop" href="#epp-xl.REF.whatley.2010.642">Whatley et al 2010</a>].</div></li><li class="half_rhythm"><div>In the US, XLP accounts for about 10% of individuals with the erythropoietic protoporphyria <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> [<a class="bk_pop" href="#epp-xl.REF.balwani.2017.789">Balwani et al 2017</a>].</div></li></ul></div></div><div id="epp-xl.Genetically_Related_Allelic_Disor"><h2 id="_epp-xl_Genetically_Related_Allelic_Disor_">Genetically Related (Allelic) Disorders</h2><p><a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> sideroblastic anemia, the only other <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> known to be associated with pathogenic variants in <i>ALAS2</i>, is caused by pathogenic <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> variants throughout <i>ALAS2.</i></p></div><div id="epp-xl.Differential_Diagnosis"><h2 id="_epp-xl_Differential_Diagnosis_">Differential Diagnosis</h2><p>Other causes of the <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> protoporphyria (XLP) <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> include the following:</p><ul><li class="half_rhythm"><div>Polymorphous light eruption</div></li><li class="half_rhythm"><div>Solar urticaria</div></li><li class="half_rhythm"><div>Drug-induced photosensitivity</div></li></ul><p><b>The <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of acquired late-onset cutaneous photosensitivity and elevated erythrocyte protoporphyrins,</b> observed on occasion in myelodysplastic syndrome, is caused by <a class="def" href="/books/n/gene/glossary/def-item/somatic-pathogenic-variant/">somatic pathogenic variant</a>(s) or <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> 18 deletions that decrease ferrochelatase activity, presumably resulting from the <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> instability associated with this syndrome [<a href="https://www.ncbi.nlm.nih.gov/books/NBK100826/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Aplin et al 2001</a>, <a class="bk_pop" href="#epp-xl.REF.sarkany.2006.464">Sarkany et al 2006</a>, <a class="bk_pop" href="#epp-xl.REF.blagojevic.2010.743">Blagojevic et al 2010</a>].</p><p>Late-onset XLP with photosensitivity and elevated protoporphyrin levels has been reported in an instance of emerging myelodysplastic syndrome with <a class="def" href="/books/n/gene/glossary/def-item/somatic-mosaicism/">somatic mosaicism</a> of a <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> <i>ALAS2</i> variant in the bone marrow [<a class="bk_pop" href="#epp-xl.REF.livideanu.2013.1688">Livideanu et al 2013</a>].</p><p><a href="/books/n/gene/epp-ar/"><b>Erythropoietic protoporphyria, autosomal recessive</b></a>
<b>(EPP-AR)</b> is caused by <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>FECH</i> (encoding ferrochelatase). The photosensitivity and cutaneous manifestations are clinically indistinguishable from those seen in males with XLP. The only significant phenotypic difference is that only about 20%-30% of individuals with EPP-AR have some degree of liver dysfunction, which is typically mild with slight elevations of the liver enzymes; however, up to 5% may develop more advanced liver disease.</p><p>In EPP-AR free protoporphyrin levels are elevated significantly as compared to zinc-chelated protoporphyrin (<a class="figpopup" href="/books/NBK121284/table/epp-xl.T.biochemical_characteristics_of_1/?report=objectonly" target="object" rid-figpopup="figeppxlTbiochemicalcharacteristicsof1" rid-ob="figobeppxlTbiochemicalcharacteristicsof1">Table 3</a>).</p><div id="epp-xl.T.biochemical_characteristics_of_1" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Biochemical Characteristics of Autosomal Recessive Erythropoietic Protoporphyria (EPP-AR)</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK121284/table/epp-xl.T.biochemical_characteristics_of_1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__epp-xl.T.biochemical_characteristics_of_1_lrgtbl__"><table><thead><tr><th id="hd_h_epp-xl.T.biochemical_characteristics_of_1_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Deficient<br />Enzyme</th><th id="hd_h_epp-xl.T.biochemical_characteristics_of_1_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Enzyme Activity</th><th id="hd_h_epp-xl.T.biochemical_characteristics_of_1_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Erythrocytes</th><th id="hd_h_epp-xl.T.biochemical_characteristics_of_1_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Urine</th><th id="hd_h_epp-xl.T.biochemical_characteristics_of_1_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Stool</th><th id="hd_h_epp-xl.T.biochemical_characteristics_of_1_1_1_1_6" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Other</th></tr></thead><tbody><tr><td headers="hd_h_epp-xl.T.biochemical_characteristics_of_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Ferro-<br />chelatase</td><td headers="hd_h_epp-xl.T.biochemical_characteristics_of_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~10%-30% of normal</td><td headers="hd_h_epp-xl.T.biochemical_characteristics_of_1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Free protoporphyrin increased: &#x0003e;90% free, &#x0003c;10% zinc-chelated</td><td headers="hd_h_epp-xl.T.biochemical_characteristics_of_1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Protoporphyrins normal</td><td headers="hd_h_epp-xl.T.biochemical_characteristics_of_1_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Protoporphyrin normal or increased</td><td headers="hd_h_epp-xl.T.biochemical_characteristics_of_1_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Plasma porphyrins increased</td></tr></tbody></table></div></div><p><b>Possible additional genetic loci.</b> It is presumed that additional loci may be responsible for the EPP <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> (i.e., cutaneous photosensitivity and elevated erythrocyte protoporphyrins). Molecular epidemiology studies in the UK have identified <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>FECH</i> pathogenic variants or an <i>ALAS2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in only 94% of individuals with the EPP phenotype [<a class="bk_pop" href="#epp-xl.REF.whatley.2010.642">Whatley et al 2010</a>]. Studies in the North American population showed that 4% of persons with the EPP phenotype and elevated protoporphyrin levels did not have a detectable FECH or ALAS2 pathogenic variant.</p><p>Recently a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> was identified in CLPX, a heme biosynthesis modulator, in a family with elevated protoporphyrin levels and the EPP <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner [<a class="bk_pop" href="#epp-xl.REF.yien.2017.e8045">Yien et al 2017</a>].</p></div><div id="epp-xl.Management"><h2 id="_epp-xl_Management_">Management</h2><div id="epp-xl.Evaluations_Following_Initial_Dia"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs of an individual diagnosed with <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> protoporphyria (XLP), the evaluations summarized in this section (if not performed as part of the evaluation that led to the diagnosis) are recommended [<a class="bk_pop" href="#epp-xl.REF.balwani.2019">Balwani 2019</a>]:</p><ul><li class="half_rhythm"><div>Comprehensive medical history including history of phototoxicity</div></li><li class="half_rhythm"><div>Complete physical examination, including thorough skin examination</div></li><li class="half_rhythm"><div>Assessment of erythrocyte protoporphyrin levels (free and zinc-chelated), complete blood count with indices to evaluate for anemia, and iron profile (including ferritin) to monitor iron stores</div></li><li class="half_rhythm"><div>Assessment for liver disease:</div><ul><li class="half_rhythm"><div>Hepatic function panel (including serum aminotransferases)</div></li><li class="half_rhythm"><div>Imaging studies such as abdominal ultrasound examination if cholelithiasis is suspected</div></li><li class="half_rhythm"><div>Newer imaging modalities such as Fibroscan<sup>&#x000ae;</sup> may be useful in evaluating liver fibrosis; however, this has not been validated in <a href="/books/n/gene/epp-ar/">erythropoietic protoporphyria, autosomal recessive</a> (EPP-AR) or XLP.</div></li><li class="half_rhythm"><div>A liver biopsy may be indicated to evaluate for protoporphyric liver disease.</div></li></ul></li><li class="half_rhythm"><div>Vitamin D studies to evaluate for deficiency as <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals are predisposed to vitamin D insufficiency due to sun avoidance</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="epp-xl.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p><b>Acute photosensitivity.</b> Although several treatments have been proposed, most have been tried only in a single individual or a small number of patients.</p><ul><li class="half_rhythm"><div>Use of protective clothing including long sleeves, gloves, and wide-brimmed hats is indicated.</div></li><li class="half_rhythm"><div>Protective tinted glass for cars and windows prevents exposure to UV light. Gray or smoke-colored filters provide only partial protection.</div></li><li class="half_rhythm"><div>Topical sunscreens are typically not useful; however, some tanning products containing creams that cause increased pigmentation may be helpful. Sun creams containing a physical reflecting agent (e.g., zinc oxide) are often effective but are not cosmetically acceptable to all.</div></li><li class="half_rhythm"><div>Oral Lumitene&#x02122; (&#x003b2;-carotene) (120&#x02013;180 mg/dL) has been used to improve tolerance to sunlight if the dose is adjusted to maintain serum carotene levels in the range of 10-15 &#x003bc;mol/L (600&#x02013;800 &#x003bc;g/dL), causing mild skin discoloration due to carotenemia. The beneficial effects of &#x003b2;-carotene may involve quenching of singlet oxygen or free radicals. However, a systematic review of about 25 studies showed that the available data are unable to prove efficacy of treatments including beta-carotene, N-acetyl cysteine, and vitamin C [<a class="bk_pop" href="#epp-xl.REF.minder.2009.84">Minder et al 2009</a>].</div></li><li class="half_rhythm"><div>Afamelanotide (Scenesse), a controlled-release, long-acting, &#x003b1;-melanocyte-stimulating hormone analogue, increases eumelanin by binding to the melanocortin-1 receptor and provides photoprotection by increasing pigmentation and antioxidant properties [<a class="bk_pop" href="#epp-xl.REF.harms.2009.1434">Harms et al 2009</a>, <a class="bk_pop" href="#epp-xl.REF.minder.2010.1591">Minder 2010</a>].</div></li></ul><p>Afamelanotide showed positive results in Phase III clinical trials in the US and Europe [<a class="bk_pop" href="#epp-xl.REF.langendonk.2015.48">Langendonk et al 2015</a>]. Long-term studies in Europe show good compliance, clinical effectiveness, and improved quality of life [<a class="bk_pop" href="#epp-xl.REF.biolcati.2015.1601">Biolcati et al 2015</a>]. It was approved for patients with the EPP <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> by the European Medicines Agency in 2014, and by the FDA in October 2019.</p><p><b>Hepatic disease.</b> Treatment of hepatic complications, which may be accompanied by motor neuropathy, is difficult.</p><ul><li class="half_rhythm"><div>Cholestyramine and other porphyrin absorbents, such as activated charcoal, may interrupt the enterohepatic circulation of protoporphyrin and promote its fecal excretion, leading to some improvement [<a class="bk_pop" href="#epp-xl.REF.mccullough.1988.177">McCullough et al 1988</a>].</div></li><li class="half_rhythm"><div>Plasmapheresis and intravenous hemin are sometimes beneficial [<a class="bk_pop" href="#epp-xl.REF.do.2002.469">Do et al 2002</a>].</div></li><li class="half_rhythm"><div>Liver transplantation has been performed as a lifesaving measure in individuals with severe protoporphyric liver disease [<a class="bk_pop" href="#epp-xl.REF.mcguire.2005.1590">McGuire et al 2005</a>, <a class="bk_pop" href="#epp-xl.REF.wahlin.2011b.1021">Wahlin et al 2011b</a>]. However, many transplant recipients experience a recurrence of the protoporphyric liver disease in the transplanted liver. Combined bone marrow and liver transplantation is indicated in patients with liver failure to prevent future damage to the allografts [<a class="bk_pop" href="#epp-xl.REF.rand.2006.e1896">Rand et al 2006</a>], and sequential liver and bone marrow transplantation has been successful in curing protoporphyric liver disease [<a class="bk_pop" href="#epp-xl.REF.wahlin.2010.393">Wahlin &#x00026; Harper 2010</a>].</div></li><li class="half_rhythm"><div>Bone marrow transplantation has also been attempted without liver transplantation in some instances. A child age two years with XLP and stage IV hepatic fibrosis was treated with a hematopoietic progenitor cell transplantation that stabilized his liver disease, thus avoiding liver transplantation [<a class="bk_pop" href="#epp-xl.REF.butler.2015.e106">Butler et al 2015</a>].</div></li></ul><p><b>Other</b></p><ul><li class="half_rhythm"><div class="half_rhythm">Vitamin D supplementation is advised as patients are predisposed to vitamin D insufficiency due to sun avoidance.</div></li><li class="half_rhythm"><div class="half_rhythm">Immunization for hepatitis A and B is recommended.</div></li><li class="half_rhythm"><div class="half_rhythm">Iron supplementation may be attempted in persons with XLP who have anemia and low ferritin levels.</div><div class="half_rhythm"><a class="bk_pop" href="#epp-xl.REF.whatley.2008.408">Whatley et al [2008]</a> reported some evidence of diminished iron stores in males with XLP; in one patient with iron deficiency, iron repletion decreased protoporphyrin accumulation and corrected the anemia. Subsequent reports indicate that iron supplementation can improve protoporphyrin levels, liver damage, and anemia in XLP [<a class="bk_pop" href="#epp-xl.REF.landefeld.2016.482">Landefeld et al 2016</a>]. A pilot study using oral iron supplementation in persons with XLP showed a reduction in protoporphyrin levels [<a class="bk_pop" href="#epp-xl.REF.balwani.2019">Balwani 2019</a>].</div></li></ul></div><div id="epp-xl.Surveillance"><h3>Surveillance</h3><div id="epp-xl.T.recommended_surveillance_for_in" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p>Recommended Surveillance for Individuals with X-Linked Protoporphyria</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK121284/table/epp-xl.T.recommended_surveillance_for_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__epp-xl.T.recommended_surveillance_for_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_epp-xl.T.recommended_surveillance_for_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">System/Concern</th><th id="hd_h_epp-xl.T.recommended_surveillance_for_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluation</th><th id="hd_h_epp-xl.T.recommended_surveillance_for_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Frequency</th></tr></thead><tbody><tr><td headers="hd_h_epp-xl.T.recommended_surveillance_for_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Erythrocyte</b><br /><b>protoporphyrin levels /</b><br /><b>Plasma total porphyrins</b></td><td headers="hd_h_epp-xl.T.recommended_surveillance_for_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Both free &#x00026; zinc-chelated</td><td headers="hd_h_epp-xl.T.recommended_surveillance_for_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Yearly</td></tr><tr><td headers="hd_h_epp-xl.T.recommended_surveillance_for_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Anemia</b></td><td headers="hd_h_epp-xl.T.recommended_surveillance_for_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Complete blood count w/indices</td><td headers="hd_h_epp-xl.T.recommended_surveillance_for_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Yearly</td></tr><tr><td headers="hd_h_epp-xl.T.recommended_surveillance_for_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Iron store depletion</b></td><td headers="hd_h_epp-xl.T.recommended_surveillance_for_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Serum ferritin levels</td><td headers="hd_h_epp-xl.T.recommended_surveillance_for_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Yearly</td></tr><tr><td headers="hd_h_epp-xl.T.recommended_surveillance_for_in_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Hepatic involvement</b></td><td headers="hd_h_epp-xl.T.recommended_surveillance_for_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hepatic function (liver transaminases)</td><td headers="hd_h_epp-xl.T.recommended_surveillance_for_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Yearly</td></tr><tr><td headers="hd_h_epp-xl.T.recommended_surveillance_for_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">US examination (if cholelithiasis is suspected)</td><td headers="hd_h_epp-xl.T.recommended_surveillance_for_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">As indicated</td></tr><tr><td headers="hd_h_epp-xl.T.recommended_surveillance_for_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Fibroscan<sup>&#x000ae;</sup> to evaluate for hepatic fibrosis</td><td headers="hd_h_epp-xl.T.recommended_surveillance_for_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">As indicated</td></tr><tr><td headers="hd_h_epp-xl.T.recommended_surveillance_for_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Vitamin D deficiency</b></td><td headers="hd_h_epp-xl.T.recommended_surveillance_for_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Vitamin D 25-OH levels whether or not receiving supplements</td><td headers="hd_h_epp-xl.T.recommended_surveillance_for_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Yearly</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">US = ultrasound</p></div></dd></dl></div></div></div></div><div id="epp-xl.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>The following are appropriate:</p><ul><li class="half_rhythm"><div>Avoidance of sunlight and UV light</div></li><li class="half_rhythm"><div>In patients with hepatic dysfunction, avoidance of alcohol and drugs that may induce cholestasis (e.g., estrogens)</div></li><li class="half_rhythm"><div>In patients with cholestatic liver failure, use of protective filters for artificial lights in the operating room to prevent phototoxic damage during procedures such as endoscopy and surgery [<a class="bk_pop" href="#epp-xl.REF.wahlin.2008.1340">Wahlin et al 2008</a>]</div></li></ul></div><div id="epp-xl.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to clarify the genetic status of at-risk newborn or infant family members in order to identify as early as possible those who would benefit from early intervention (sun protection) and routine monitoring (<a class="figpopup" href="/books/NBK121284/table/epp-xl.T.recommended_surveillance_for_in/?report=objectonly" target="object" rid-figpopup="figeppxlTrecommendedsurveillanceforin" rid-ob="figobeppxlTrecommendedsurveillanceforin">Table 4</a>).</p><p>Evaluations include:</p><ul><li class="half_rhythm"><div>Targeted <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> if the <i>ALAS2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member;</div></li><li class="half_rhythm"><div>Detection of markedly elevated erythrocyte protoporphyrin levels with a predominance of metal-free protoporphyrin if the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family is not known.</div></li></ul><p>See <a href="#epp-xl.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="epp-xl.Pregnancy_Management"><h3>Pregnancy Management</h3><p>There is no information on pregnancy management in XLP. Based on experience with <a href="/books/n/gene/epp-ar/">autosomal recessive EPP</a>, pregnancy is unlikely to be complicated by XLP [<a class="bk_pop" href="#epp-xl.REF.pohfitzpatrick.1997.40">Poh-Fitzpatrick 1997</a>].</p></div><div id="epp-xl.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>A Phase II clinical trial with MT-7117, an oral small molecule that works as a melanocortin 1 receptor agonist and increases skin pigmentation, has been completed. A Phase III clinical trial for adults and children is planned for MT-7117.</p><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="epp-xl.Genetic_Counseling"><h2 id="_epp-xl_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="epp-xl.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>By definition, <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> protoporphyria is inherited in an X-linked manner.</p></div><div id="epp-xl.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The father of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male will not have the disorder nor will he be <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> for the <i>ALAS2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>; therefore, he does not require further evaluation/testing.</div></li><li class="half_rhythm"><div>In a family with more than one <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual, the mother of an affected male is an <a class="def" href="/books/n/gene/glossary/def-item/obligate-heterozygote/">obligate heterozygote</a>. Note: If a woman has more than one affected child and no other affected relatives and if the <i>ALAS2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> cannot be detected in her leukocyte DNA, she most likely has <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>. No data on the frequency of germline mosaicism in XLP are available.</div></li><li class="half_rhythm"><div>If a male is the only <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member (i.e., a <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case), the mother may be a <a class="def" href="/books/n/gene/glossary/def-item/heterozygote/">heterozygote</a> or the affected male may have a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>
<i>ALAS2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, in which case the mother is not <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a>. No data on the frequency of <i>de nov</i>o pathogenic variants in XLP are available.</div></li></ul><p><b>Parents of a female <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>A female <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> may have inherited the <i>ALAS2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> from either her mother or her father, or the pathogenic variant may be <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>.</div></li><li class="half_rhythm"><div>Detailed evaluation of the parents and review of the extended family history may help to distinguish probands with a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> from those with an inherited pathogenic variant. Molecular genetic testing of the mother (and possibly the father, or subsequently the father) can determine if the <i>ALAS2</i> pathogenic variant was inherited.</div></li></ul><p><b>Sibs of a male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to sibs depends on the genetic status of the mother:</p><ul><li class="half_rhythm"><div>If the mother of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has an <i>ALAS2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the chance of transmitting it in each pregnancy is 50%. Males who inherit the pathogenic variant will be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>; females who inherit the pathogenic variant will be heterozygotes and may be asymptomatic or have clinical manifestations of the disorder ranging from mild to severe depending on favorable vs nonfavorable <a class="def" href="/books/n/gene/glossary/def-item/x-chromosome-inactivation/">X-chromosome inactivation</a> (see <a href="#epp-xl.Penetrance">Penetrance</a>).</div></li><li class="half_rhythm"><div>If a male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> represents a <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case and if the <i>ALAS2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> cannot be detected in the leukocyte DNA of the mother, the risk to sibs is slightly greater than that of the general population (though still &#x0003c;1%) because of the possibility of maternal <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>.</div></li></ul><p><b>Sibs of a female <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to sibs depends on the genetic status of the parents:</p><ul><li class="half_rhythm"><div>If the mother of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has an <i>ALAS2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the chance of transmitting it in each pregnancy is 50%. Males who inherit the pathogenic variant will be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>; females who inherit the pathogenic variant will be heterozygotes (see <b>Sibs of a male proband</b>).</div></li><li class="half_rhythm"><div>If the father of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has an <i>ALAS2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, he will transmit the variant to all of his daughters and none of his sons.</div></li><li class="half_rhythm"><div>If a female <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> represents a <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case and if the <i>ALAS2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> cannot be detected in the leukocyte DNA of either parent, the risk to sibs is slightly greater than that of the general population (though still &#x0003c;1%) because of the possibility of parental <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>.</div></li></ul><p><b>Offspring of a male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Affected males transmit the <i>ALAS2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> to:</p><ul><li class="half_rhythm"><div>All of their daughters, who will be heterozygotes and may be asymptomatic or have clinical manifestations of the disorder ranging from mild to severe depending on favorable vs nonfavorable <a class="def" href="/books/n/gene/glossary/def-item/x-chromosome-inactivation/">X-chromosome inactivation</a> (see <a href="#epp-xl.Penetrance">Penetrance</a>);</div></li><li class="half_rhythm"><div>None of their sons.</div></li></ul><p><b>Offspring of a female <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Women with an <i>ALAS2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> have a 50% chance of transmitting the pathogenic variant to each child:</p><ul><li class="half_rhythm"><div>Males who inherit the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> will be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>. Note: Asymptomatic or mildly symptomatic females are at risk for having affected male children who may have early-onset, more severe symptoms.</div></li><li class="half_rhythm"><div>Females who inherit the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> will be heterozygotes (see <b>Offspring of a male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b>).</div></li></ul><p><b>Other family members</b></p><ul><li class="half_rhythm"><div>The risk to other family members depends on the status of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents: if a parent has the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, his or her family members may be at risk.</div></li><li class="half_rhythm"><div>Note: Molecular genetic testing may be able to identify the family member in whom a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> arose, information that could help determine genetic risk status of the extended family.</div></li></ul></div><div id="epp-xl.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#epp-xl.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or at risk of having the <i>ALAS2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="epp-xl.Prenatal_Testing_and_Preimplantat"><h3>Prenatal Testing and Preimplantation Genetic Testing</h3><p>Once the <i>ALAS2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-testing/">preimplantation genetic testing</a> are possible.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="epp-xl.Resources"><h2 id="_epp-xl_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>American Porphyria Foundation (APF)</b></div><div>915 St. Elmo Avenue</div><div>Suite 200</div><div>Bethesda MD 20814</div><div><b>Phone:</b> 866-APF-3635 (toll-free); 301-347-7166</div><div><b>Email:</b> porphyrus@porphyriafoundation.com</div><div><a href="https://www.porphyriafoundation.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.porphyriafoundation.org</a></div></li><li class="half_rhythm"><div><b>European Porphyria Network</b></div><div><b>Email:</b> contact@porphyria.eu</div><div><a href="http://porphyria.eu/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">porphyria.eu</a></div></li><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="http://ghr.nlm.nih.gov/condition=acuteintermittentporphyria;jsessionid=D4E2E078605EC9CE8599D96BB81EBC0E" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Porphyria</a></div></li><li class="half_rhythm"><div><b>Swedish Porphyria Patients' Association</b></div><div>Karolinska Universitetssjukhuset</div><div>Huddinge M 96</div><div>Stockholm Stockholms Lan SE-141 86</div><div>Sweden</div><div><b>Phone:</b> +46 8 711 56 09 </div><div><b>Email:</b> porfyrisjukdomar@gmail.com</div><div><a href="http://www.porfyri.se" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.porfyri.se</a></div></li></ul></div><div id="epp-xl.Molecular_Genetics"><h2 id="_epp-xl_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="epp-xl.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>X-Linked Protoporphyria: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK121284/table/epp-xl.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__epp-xl.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_epp-xl.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_epp-xl.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_epp-xl.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_epp-xl.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_epp-xl.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_epp-xl.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_epp-xl.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/212" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>ALAS2</i></a></td><td headers="hd_b_epp-xl.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=212" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Xp11<wbr style="display:inline-block"></wbr>​.21</a></td><td headers="hd_b_epp-xl.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P22557" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">5-aminolevulinate synthase, erythroid-specific, mitochondrial</a></td><td headers="hd_b_epp-xl.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/ALAS2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ALAS2 database</a></td><td headers="hd_b_epp-xl.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=ALAS2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ALAS2</a></td><td headers="hd_b_epp-xl.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=ALAS2[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ALAS2</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="epp-xl.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="epp-xl.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for X-Linked Protoporphyria (<a href="/omim/300752,301300" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK121284/table/epp-xl.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__epp-xl.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/300752" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">300752</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PROTOPORPHYRIA, ERYTHROPOIETIC, X-LINKED; XLEPP</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/301300" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">301300</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DELTA-AMINOLEVULINATE SYNTHASE 2; ALAS2</td></tr></tbody></table></div></div><div id="epp-xl.Molecular_Pathogenesis"><h3>Molecular Pathogenesis</h3><p><i>ALAS2</i> encodes an erythroid-specific 5-aminolevulinate synthase; the normal isoform (<a href="/protein/NP_000023.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000023.2</a>) has 587 amino acid residues, including a 49-amino acid transit peptide. The C-terminal amino acids encoded by <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 11 interact with the active site or other cofactors in a manner that regulates the activity of the enzyme.</p><p>Disease-associated alteration of erythroid-specific 5-aminolevulinate synthase C-terminal amino acids results in increased ALAS2 enzyme activity [<a class="bk_pop" href="#epp-xl.REF.whatley.2008.408">Whatley et al 2008</a>, <a class="bk_pop" href="#epp-xl.REF.balwani.2013.26">Balwani et al 2013</a>, <a class="bk_pop" href="#epp-xl.REF.bishop.2013.18">Bishop et al 2013</a>] and systemic accumulation of free and zinc-chelated protoporphyrins, particularly in erythroid and hepatic cells. The rate of 5-aminolevulinic acid formation is increased to such an extent that insertion of iron into protoporphyrin becomes rate limiting for heme synthesis, resulting in the accumulation of protoporphyrins [<a class="bk_pop" href="#epp-xl.REF.whatley.2008.408">Whatley et al 2008</a>].</p><p><b>Mechanism of disease causation.</b> All <i>ALAS2</i> pathogenic variants associated with XLP are located in the last <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> (exon 11 of <a href="/nuccore/NM_000032.4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000032.4</a>) and result in a <a class="def" href="/books/n/gene/glossary/def-item/gain-of-function/">gain-of-function</a> effect. Reported disease-associated variants to date include <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and several small <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> variants (<a class="figpopup" href="/books/NBK121284/table/epp-xl.T.notable_alas2_pathogenic_varian/?report=objectonly" target="object" rid-figpopup="figeppxlTnotablealas2pathogenicvarian" rid-ob="figobeppxlTnotablealas2pathogenicvarian">Table 5</a>).</p><p><b><i>ALAS2</i>-specific laboratory technical considerations.</b> Variants causing XLP have only been observed in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 11 (<a href="/nuccore/NM_000032.4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000032.4</a>), which encodes the C terminus of the protein [<a class="bk_pop" href="#epp-xl.REF.balwani.2019">Balwani 2019</a>].</p><div id="epp-xl.T.notable_alas2_pathogenic_varian" class="table"><h3><span class="label">Table 5. </span></h3><div class="caption"><p>Notable <i>ALAS2</i> Pathogenic Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK121284/table/epp-xl.T.notable_alas2_pathogenic_varian/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__epp-xl.T.notable_alas2_pathogenic_varian_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_epp-xl.T.notable_alas2_pathogenic_varian_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference<br />Sequences</th><th id="hd_h_epp-xl.T.notable_alas2_pathogenic_varian_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide<br />Change</th><th id="hd_h_epp-xl.T.notable_alas2_pathogenic_varian_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted<br />Protein Change</th><th id="hd_h_epp-xl.T.notable_alas2_pathogenic_varian_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Comment</th></tr></thead><tbody><tr><td headers="hd_h_epp-xl.T.notable_alas2_pathogenic_varian_1_1_1_1" rowspan="5" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_000032.4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000032<wbr style="display:inline-block"></wbr>​.4</a><br /><a href="/protein/NP_000023.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000023<wbr style="display:inline-block"></wbr>​.2</a></td><td headers="hd_h_epp-xl.T.notable_alas2_pathogenic_varian_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">c.1642C&#x0003e;T</td><td headers="hd_h_epp-xl.T.notable_alas2_pathogenic_varian_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">p.Glu548Ter</td><td headers="hd_h_epp-xl.T.notable_alas2_pathogenic_varian_1_1_1_4" rowspan="5" colspan="1" style="text-align:left;vertical-align:middle;">XLP disease-associated<br />variants in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 11 that<br />have a <a class="def" href="/books/n/gene/glossary/def-item/gain-of-function/">gain-of-function</a><br />effect</td></tr><tr><td headers="hd_h_epp-xl.T.notable_alas2_pathogenic_varian_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:top;">c.1651_1676del</td><td headers="hd_h_epp-xl.T.notable_alas2_pathogenic_varian_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">p. Ser551ProfsTer6</td></tr><tr><td headers="hd_h_epp-xl.T.notable_alas2_pathogenic_varian_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:top;">c.1699_1700delAT</td><td headers="hd_h_epp-xl.T.notable_alas2_pathogenic_varian_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">p.Met567GlufsTer2</td></tr><tr><td headers="hd_h_epp-xl.T.notable_alas2_pathogenic_varian_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:top;">c.1706_1709delAGTG</td><td headers="hd_h_epp-xl.T.notable_alas2_pathogenic_varian_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">p.Glu569GlyfsTer24</td></tr><tr><td headers="hd_h_epp-xl.T.notable_alas2_pathogenic_varian_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:top;">c.1736delG</td><td headers="hd_h_epp-xl.T.notable_alas2_pathogenic_varian_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">p.Gln581SerfsTer13</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd></dl></div></div></div></div></div><div id="epp-xl.References"><h2 id="_epp-xl_References_">References</h2><div id="epp-xl.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="epp-xl.REF.anderson.2001">Anderson KE, Sassa S, Bishop DF, Desnick RJ. Disorders of heme biosynthesis: X-linked sideroblastic anemias and the porphyrias. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Vogelstein B, eds. <em>The Metabolic and Molecular Bases of Inherited Disease</em>. 8 ed. New York, NY: McGraw-Hill; 2001:2991-3062.</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-xl.REF.balwani.2019">Balwani M. Effects of iron supplementation in EPP and XLP. Milan, Italy: International Congress on Porphyrins and Porphyria: From Bench to Care. 2019.</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-xl.REF.balwani.2013.26">Balwani M, Doheny D, Bishop DF, Nazarenko I, Yasuda M, Dailey HA, Anderson KE, Bissell DM, Bloomer J, Bonkovsky HL, Phillips JD, Liu L, Desnick RJ. Loss-of-function ferrochelatase and gain-of-function erythroid 5-aminolevulinate synthase mutations causing erythropoietic protoporphyria and X-linked protoporphyria in North American patients reveal novel mutations and a high prevalence of X-linked protoporphyria. <span><span class="ref-journal">Mol Med. </span>2013;<span class="ref-vol">19</span>:26–35.</span> [<a href="/pmc/articles/PMC3646094/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3646094</span></a>] [<a href="/pubmed/23364466" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23364466</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-xl.REF.balwani.2017.789">Balwani M, Naik H, Anderson KE, Bissell DM, Bloomer J, Bonkovsky HL, Phillips JD, Overbey JR, Wang B, Singal AK, Liu LU, Desnick RJ. Clinical, biochemical, and genetic characterization of North American patients with erythropoietic protoporphyria and X-linked protoporphyria. <span><span class="ref-journal">JAMA Dermatol. </span>2017;<span class="ref-vol">153</span>:789–96.</span> [<a href="/pmc/articles/PMC5710403/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5710403</span></a>] [<a href="/pubmed/28614581" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28614581</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-xl.REF.biolcati.2015.1601">Biolcati G, Marchesini E, Sorge F, Barbieri L, Schneider-Yin X, Minder EI. Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria. <span><span class="ref-journal">Br J Dermatol. </span>2015;<span class="ref-vol">172</span>:1601–12.</span> [<a href="/pubmed/25494545" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25494545</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-xl.REF.bishop.2013.18">Bishop DF, Tchaikovskii V, Nazarenko I, Desnick RJ. Molecular expression and characterization of erythroid-specific 5-aminolevulinate synthase gain-of-function mutations causing X-linked protoporphyria. <span><span class="ref-journal">Mol Med. </span>2013;<span class="ref-vol">19</span>:18–25.</span> [<a href="/pmc/articles/PMC3592931/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3592931</span></a>] [<a href="/pubmed/23348515" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23348515</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-xl.REF.blagojevic.2010.743">Blagojevic D, Schenk T, Haas O, Zierhofer B, Konnaris C, Trautinger F. Acquired erythropoietic protoporphyria. <span><span class="ref-journal">Ann Hematol. </span>2010;<span class="ref-vol">89</span>:743–4.</span> [<a href="/pubmed/19902211" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19902211</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-xl.REF.butler.2015.e106">Butler DF, Ginn KF, Daniel JF, Bloomer JR, Kats A, Shreve N, Myers GD. Bone marrow transplant for X-linked protoporphyria with severe hepatic fibrosis. <span><span class="ref-journal">Pediatr Transplant. </span>2015;<span class="ref-vol">19</span>:E106–10.</span> [<a href="/pubmed/25856424" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25856424</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-xl.REF.di_pierro.2009.315">Di Pierro E, Brancaleoni V, Tavazzi D, Cappellini M. C-terminal deletion in the ALAS2 gene and X-linked dominant protoporphyria. <span><span class="ref-journal">Haematologica. </span>2009;<span class="ref-vol">94</span> Suppl 2:315.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="epp-xl.REF.do.2002.469">Do KD, Banner BF, Katz E, Szymanski IO, Bonkovsky HL. Benefits of chronic plasmapheresis and intravenous heme-albumin in erythropoietic protoporphyria after orthotopic liver transplantation. <span><span class="ref-journal">Transplantation. </span>2002;<span class="ref-vol">73</span>:469–72.</span> [<a href="/pubmed/11884947" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11884947</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-xl.REF.gou.2018.213">Gou E, Weng C, Greene T, Anderson KE, Phillips JD. Longitudinal analysis of erythrocyte and plasma protoporphyrin levels in patients with protoporphyria. <span><span class="ref-journal">J Appl Lab Med. </span>2018;<span class="ref-vol">3</span>:213–21.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="epp-xl.REF.harms.2009.1434">Harms JH, Lautenschlager S, Minder CE, Minder EI. Mitigating photosensitivity of erythropoietic protoporphyria patients by an agonistic analog of alpha-melanocyte stimulating hormone. <span><span class="ref-journal">Photochem Photobiol. </span>2009;<span class="ref-vol">85</span>:1434–9.</span> [<a href="/pubmed/19656325" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19656325</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-xl.REF.holme.2008.211">Holme SA, Anstey AV, Badminton MN, Elder GH. Serum 25-hydroxyvitamin D in erythropoietic protoporphyria. <span><span class="ref-journal">Br J Dermatol. </span>2008;<span class="ref-vol">159</span>:211.</span> [<a href="/pubmed/18476956" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18476956</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-xl.REF.landefeld.2016.482">Landefeld C, Kentouche K, Gruhn B, Stauch T, R&#x000f6;&#x000df;ler S, Schuppan D, Whatley SD, Beck JF, St&#x000f6;lzel U. X-linked protoporphyria: iron supplementation improves protoporphyrin overload, liver damage and anaemia. <span><span class="ref-journal">Br J Haematol. </span>2016;<span class="ref-vol">173</span>:482–4.</span> [<a href="/pubmed/26193873" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26193873</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-xl.REF.langendonk.2015.48">Langendonk JG, Balwani M, Anderson KE, Bonkovsky HL, Anstey AV, Bissell DM, Bloomer J, Edwards C, Neumann NJ, Parker C, Phillips JD, Lim HW, Hamzavi I, Deybach JC, Kauppinen R, Rhodes LE, Frank J, Murphy GM, Karstens FPJ, Sijbrands EJG, de Rooij FWM, Lebwohl M, Naik H, Goding CR, Wilson JHP, Desnick RJ. Afamelanotide for erythropoietic protoporphyria. <span><span class="ref-journal">N Engl J Med. </span>2015;<span class="ref-vol">373</span>:48–59.</span> [<a href="/pmc/articles/PMC4780255/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4780255</span></a>] [<a href="/pubmed/26132941" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26132941</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-xl.REF.livideanu.2013.1688">Livideanu CB, Ducamp S, Lamant L, Gouya L, Rauzy OB, Deybach JC, Paul C, Puy H, Marguery MC. Late-onset X-linked dominant protoporphyria: an etiology of photosensitivity in the elderly. <span><span class="ref-journal">J Invest Dermatol. </span>2013;<span class="ref-vol">133</span>:1688–90.</span> [<a href="/pubmed/23223129" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23223129</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-xl.REF.mccullough.1988.177">McCullough AJ, Barron D, Mullen KD, Petrelli M, Park MC, Mukhtar H, Bickers DR. Fecal protoporphyrin excretion in erythropoietic protoporphyria: effect of cholestyramine and bile acid feeding. <span><span class="ref-journal">Gastroenterology. </span>1988;<span class="ref-vol">94</span>:177–81.</span> [<a href="/pubmed/3335288" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3335288</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-xl.REF.mcguire.2005.1590">McGuire BM, Bonkovsky HL, Carithers RL Jr, Chung RT, Goldstein LI, Lake JR, Lok AS, Potter CJ, Rand E, Voigt MD, Davis PR, Bloomer JR. Liver transplantation for erythropoietic protoporphyria liver disease. <span><span class="ref-journal">Liver Transpl. </span>2005;<span class="ref-vol">11</span>:1590–6.</span> [<a href="/pubmed/16315313" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16315313</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-xl.REF.minder.2010.1591">Minder EI. Afamelanotide, an agonistic analog of &#x003b1;-melanocyte-stimulating hormone, in dermal phototoxicity of erythropoietic protoporphyria. <span><span class="ref-journal">Expert Opin Investig Drugs. </span>2010;<span class="ref-vol">19</span>:1591–602.</span> [<a href="/pubmed/21073357" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21073357</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-xl.REF.minder.2009.84">Minder EI, Schneider-Yin X, Steurer J, Bachmann LM. A systematic review of treatment options for dermal photosensitivity in erythropoietic protoporphyria. <span><span class="ref-journal">Cell Mol Biol (Noisy-le-grand). </span>2009;<span class="ref-vol">55</span>:84–97.</span> [<a href="/pubmed/19268006" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19268006</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-xl.REF.pohfitzpatrick.1997.40">Poh-Fitzpatrick MB. Human protoporphyria: reduced cutaneous photosensitivity and lower erythrocyte porphyrin levels during pregnancy. <span><span class="ref-journal">J Am Acad Dermatol. </span>1997;<span class="ref-vol">36</span>:40–3.</span> [<a href="/pubmed/8996259" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8996259</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-xl.REF.rand.2006.e1896">Rand EB, Bunin N, Cochran W, Ruchelli E, Olthoff KM, Bloomer JR. Sequential liver and bone marrow transplantation for treatment of erythropoietic protoporphyria. <span><span class="ref-journal">Pediatrics. </span>2006;<span class="ref-vol">118</span>:e1896–9.</span> [<a href="/pubmed/17074841" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17074841</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-xl.REF.sarkany.2006.464">Sarkany RP, Ross G, Willis F. Acquired erythropoietic protoporphyria as a result of myelodysplasia causing loss of chromosome 18. <span><span class="ref-journal">Br J Dermatol. </span>2006;<span class="ref-vol">155</span>:464–6.</span> [<a href="/pubmed/16882191" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16882191</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-xl.REF.schneideryin.2000.719">Schneider-Yin X, Gouya L, Meier-Weinand A, Deybach JC, Minder EI. New insights into the pathogenesis of erythropoietic protoporphyria and their impact on patient care. <span><span class="ref-journal">Eur J Pediatr. </span>2000;<span class="ref-vol">159</span>:719–25.</span> [<a href="/pubmed/11039124" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11039124</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-xl.REF.spelt.2010.s1">Spelt JM, de Rooij FW, Wilson JH, Zandbergen AA. Vitamin D deficiency in patients with erythropoietic protoporphyria. <span><span class="ref-journal">J Inherit Metab Dis. </span>2010;<span class="ref-vol">33</span> Suppl 3:S1–4.</span> [<a href="/pubmed/24137761" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24137761</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-xl.REF.wahlin.2011a.278">Wahlin S, Floderus Y, St&#x000e5;l P, Harper P. Erythropoietic protoporphyria in Sweden: demographic, clinical, biochemical and genetic characteristics. <span><span class="ref-journal">J Intern Med. </span>2011a;<span class="ref-vol">269</span>:278–88.</span> [<a href="/pubmed/20412370" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20412370</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-xl.REF.wahlin.2010.393">Wahlin S, Harper P. The role for BMT in erythropoietic protoporphyria. <span><span class="ref-journal">Bone Marrow Transplant. </span>2010;<span class="ref-vol">45</span>:393–4.</span> [<a href="/pubmed/19525986" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19525986</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-xl.REF.wahlin.2008.1340">Wahlin S, Srikanthan N, Hamre B, Harper P, Brun A. Protection from phototoxic injury during surgery and endoscopy in erythropoietic protoporphyria. <span><span class="ref-journal">Liver Transpl. </span>2008;<span class="ref-vol">14</span>:1340–6.</span> [<a href="/pubmed/18756472" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18756472</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-xl.REF.wahlin.2011b.1021">Wahlin S, Stal P, Adam R, Karam V, Porte R, Seehofer D, Gunson BK, Hillings&#x000f8; J, Klempnauer JL, Schmidt J, Alexander G, O'Grady J, Clavien PA, Salizzoni M, Paul A, Rolles K, Ericzon BG, Harper P, et al.  Liver transplantation for erythropoietic protoporphyria in Europe. <span><span class="ref-journal">Liver Transpl. </span>2011b;<span class="ref-vol">17</span>:1021–6.</span> [<a href="/pubmed/21604355" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21604355</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-xl.REF.whatley.2008.408">Whatley SD, Ducamp S, Gouya L, Grandchamp B, Beaumont C, Badminton MN, Elder GH, Holme SA, Anstey AV, Parker M, Corrigall AV, Meissner PN, Hift RJ, Marsden JT, Ma Y, Mieli-Vergani G, Deybach JC, Puy H. C-terminal deletions in the alas2 gene lead to gain of function and cause X-linked dominant protoporphyria without anemia or iron overload. <span><span class="ref-journal">Am J Hum Genet. </span>2008;<span class="ref-vol">83</span>:408–14.</span> [<a href="/pmc/articles/PMC2556430/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2556430</span></a>] [<a href="/pubmed/18760763" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18760763</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-xl.REF.whatley.2010.642">Whatley SD, Mason NG, Holme SA, Anstey AV, Elder GH, Badminton MN. Molecular epidemiology of erythropoietic protoporphyria in the United Kingdom. <span><span class="ref-journal">Br J Dermatol. </span>2010;<span class="ref-vol">162</span>:642–6.</span> [<a href="/pubmed/20105171" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20105171</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epp-xl.REF.yien.2017.e8045">Yien YY, Ducamp S, van der Vorm LN, Kardon JR, Manceau H, Kannengiesser C, Bergonia HA, Kafina MD, Karim Z, Gouya L, Baker TA, Puy H, Phillips JD, Nicolas G, Paw BH. Mutation in human CLPX elevates levels of delta-aminolevulinate synthase and protoporphyrin IX to promote erythropoietic protoporphyria. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2017;<span class="ref-vol">114</span>:E8045–52.</span> [<a href="/pmc/articles/PMC5617249/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5617249</span></a>] [<a href="/pubmed/28874591" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28874591</span></a>]</div></li></ul></div></div><div id="epp-xl.Chapter_Notes"><h2 id="_epp-xl_Chapter_Notes_">Chapter Notes</h2><div id="epp-xl.Acknowledgments"><h3>Acknowledgments</h3><p>The XLP contribution to <i>GeneReviews</i> was supported in part by the Porphyrias Consortium of the NIH-supported <a href="http://rarediseasesnetwork.epi.usf.edu/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Rare Diseases Clinical Research Network</a> (NIH grant: 5 U54 DK083909), including:</p><ul><li class="half_rhythm"><div>Dr Karl Anderson, University of Texas Medical Branch, Galveston, Texas</div></li><li class="half_rhythm"><div>Dr Montgomery Bissell, University of California, San Francisco, California</div></li><li class="half_rhythm"><div>Dr Herbert Bonkovsky, Carolinas Medical Center, Charlotte, North Carolina</div></li><li class="half_rhythm"><div>Dr John Phillips, University of Utah School of Medicine, Salt Lake City, Utah</div></li></ul></div><div id="epp-xl.Author_History"><h3>Author History</h3><p>Manisha Balwani, MD, MS, FACMG (2013-present)<br />Joseph Bloomer, MD; University of Alabama, Birmingham (2013-2019)<br />Robert Desnick, MD, PhD, FACMG (2013-present)<br />Porphyrias Consortium of the NIH-Sponsored Rare Diseases Clinical Research Network (2013-present)</p></div><div id="epp-xl.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>27 November 2019 (bp) Comprehensive update posted live</div></li><li class="half_rhythm"><div>14 February 2013 (me) Review posted live</div></li><li class="half_rhythm"><div>19 September 2012 (rd) Original submission</div></li></ul></div></div><div><dl class="temp-labeled-list small"><dt>*</dt><dd><div id="epp-xl.Tb.an3"><p class="no_top_margin">See Chapter Notes, <a href="#epp-xl.Acknowledgments">Acknowledgments</a></p></div></dd></dl></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK121284</span><span class="label">PMID: <a href="/pubmed/23409301" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">23409301</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/opd/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/x-scid/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK121284&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK121284/?report=reader">PubReader</a></li><li><a href="/books/NBK121284/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK121284" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK121284" style="display:none" title="Cite this Page"><div class="bk_tt">Balwani M, Desnick R; Porphyrias Consortium of the NIH-Sponsored Rare Diseases Clinical Research Network. X-Linked Protoporphyria. 2013 Feb 14 [Updated 2019 Nov 27]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK121284/pdf/Bookshelf_NBK121284.pdf">PDF version of this page</a> (452K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#epp-xl.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#epp-xl.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#epp-xl.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#epp-xl.Genetically_Related_Allelic_Disor" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#epp-xl.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#epp-xl.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#epp-xl.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#epp-xl.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#epp-xl.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#epp-xl.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#epp-xl.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=212[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">ALAS2</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Variations in ClinVar</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=NBK121284+AND+genereviews[submitter]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Variations from this GeneReview in ClinVar</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=3011838" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=3011838" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=3011838" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=3011838" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/23016163" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Erythropoietic Protoporphyria, Autosomal Recessive</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Erythropoietic Protoporphyria, Autosomal Recessive<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Balwani M, Bloomer J, Desnick R, Porphyrias Consortium of the NIH-Sponsored Rare Diseases Clinical Research Network. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24027798" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Congenital Erythropoietic Porphyria</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Congenital Erythropoietic Porphyria<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Erwin A, Balwani M, Desnick RJ, Porphyrias Consortium of the NIH-Sponsored Rare Diseases Clinical Research Network. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24006547" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ornithine Transcarbamylase Deficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ornithine Transcarbamylase Deficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Lichter-Konecki U, Caldovic L, Morizono H, Simpson K. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/23409300" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Variegate Porphyria</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Variegate Porphyria<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Singal AK, Anderson KE. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/23236641" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hereditary Coproporphyria</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hereditary Coproporphyria<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Wang B, Bissell DM. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=23409301" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=23409301" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e04294875f66d18aae79232">X-Linked Protoporphyria - GeneReviews®</a><div class="ralinkpop offscreen_noflow">X-Linked Protoporphyria - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T22:30:16-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal101&amp;ncbi_phid=CE881C1BE04170D100000000085402F6&amp;ncbi_session=CE881C1BE0429481_2132SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK121284%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK121284&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK121284/&amp;ncbi_pagename=X-Linked Protoporphyria - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE881C1BE0429481_2132SID /projects/books/PBooks@5.22 portal101 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>